Serum Amyloid A Protein: A Potential Biomarker Correlated With Clinical Stage of Lung Cancer  

作　　者：DAN-HUI LIU XIAO-MIN WANG LI-JUAN ZHANG SONG-WEI DAI LI-YUN LIU JI-FU LIU SHAN-SHAN WU SHUAN-YING YANG SAM FU XUE-YUAN XIAO DA-CHENG HE 

机构地区：[1]Key Laboratory of Cell Proliferation and Regulation of Ministry of Education, Beijing Normal University, Beijing 100875, China [2]Department of Thoracic Surgery, General Hospital of Beijing Command, PLA, Beijing 100700, China [3]Department of Respiratory Medicine, Second Hospital of Xi＇an Jiaotong University, Xi＇an 710004, Shaanxi, China [4]Ciphergen Biosystems, Inc., Fremont, CA 94555, USA

出　　处：《Biomedical and Environmental Sciences》2007年第1期33-40,共8页生物医学与环境科学（英文版）

基　　金：This work was supported by the National Natural Science Foundation of China (Grant No.30370712);Beijing Key Project (Grant No. 7051002); Beijing Science Technology Committee Project (No.Y0204002040111);a grant of Majon State Basic Research Program of China (No. 2006CB 910100).

摘　　要：Objective To identify serum diagnosis or progression biomarkers in patients with lung cancer using protein chip profiling analysis. Method Profiling analysis was performed on 450 sera collected from 213 patients with lung cancer, 19 with pneumonia, 16 with pulmonary tuberculosis, 65 with laryngeal carcinoma, 55 with laryngopharyngeal carcinoma patients, and 82 normal individuals. A new strategy was developed to identify the biomarkers on chip by trypsin pre-digestion. Results Profiling analysis demonstrated that an 11.6kDa protein was significandy elevated in lung cancer patients, compared with the control groups （P〈0.001）. The level and percentage of 11.6kDa protein progressively increased with the clinical stages Ⅰ-Ⅳ and were also higher in patients with squamous cell carcinoma than in other subtypes. This biomarker could be decreased after operation or chemotherapy. On the other hand, 11.6kDa protein was also increased in 50% benign diseases of lung and 13% of other cancer controls. After trypsin pre-digestion, a set of new peptide biomarkers was noticed to appear only in the samples containing a 11.6kDa peak. Further identification showed that 2177Da was a fragment of serum amyloid A （SAA, MW 11.6kDa）. Two of the new peaks, 1550Da and 1611Da, were defined from the same protein by database searching. This result was further confirmed by partial purification of 11.6kDa protein and MS analysis. Conclusion SAA is a useful biomarker to monitor the progression of lung cancer and can directly identify some biomarkers on chip.Objective To identify serum diagnosis or progression biomarkers in patients with lung cancer using protein chip profiling analysis. Method Profiling analysis was performed on 450 sera collected from 213 patients with lung cancer, 19 with pneumonia, 16 with pulmonary tuberculosis, 65 with laryngeal carcinoma, 55 with laryngopharyngeal carcinoma patients, and 82 normal individuals. A new strategy was developed to identify the biomarkers on chip by trypsin pre-digestion. Results Profiling analysis demonstrated that an 11.6kDa protein was significandy elevated in lung cancer patients, compared with the control groups （P〈0.001）. The level and percentage of 11.6kDa protein progressively increased with the clinical stages Ⅰ-Ⅳ and were also higher in patients with squamous cell carcinoma than in other subtypes. This biomarker could be decreased after operation or chemotherapy. On the other hand, 11.6kDa protein was also increased in 50% benign diseases of lung and 13% of other cancer controls. After trypsin pre-digestion, a set of new peptide biomarkers was noticed to appear only in the samples containing a 11.6kDa peak. Further identification showed that 2177Da was a fragment of serum amyloid A （SAA, MW 11.6kDa）. Two of the new peaks, 1550Da and 1611Da, were defined from the same protein by database searching. This result was further confirmed by partial purification of 11.6kDa protein and MS analysis. Conclusion SAA is a useful biomarker to monitor the progression of lung cancer and can directly identify some biomarkers on chip.

关 键 词：Lung cancer Serum amyloid A On chip identification Surface enhanced laser desorption/ionization BIOMARKER 

分 类 号：R734.2[医药卫生—肿瘤]